Moderate hypofractionation of radiotherapy is widely considered a viable alternative to conventional fractionation for the treatment of patients with organ-confined prostate cancer, but stereotactic body radiotherapy (SBRT) is rapidly emerging as a novel treatment modality for this disease. Advances in treatment planning, image guidance, target position reproducibility and on-line tracking, coupled with a compelling radiobiological rationale, have promoted SBRT as a safe and effective treatment. Dose escalation to the tumour tissue through a decreased number of radiation fractions improves patient comfort and convenience, as well as treatment cost-effectiveness, compared with conventional radiotherapy regimens. Several clinical trials have investigated moderate and extreme hypofractionation of radiotherapy in patients with prostate cancer. Evidence is accumulating which suggests that the use of moderately hypofractionated radiotherapy can be recommended regardless of cancer risk group. Regimens of extremely hypofractionated radiotherapy have shown very good short-term efficacy and safety outcomes, but appropriately designed trials with extended follow-up monitoring are required to confirm long-term outcomes.

Arcangeli, S., Greco, C. (2016). Hypofractionated radiotherapy for organ-confined prostate cancer: Is less more?. NATURE REVIEWS. UROLOGY, 13(7), 400-408 [10.1038/nrurol.2016.106].

Hypofractionated radiotherapy for organ-confined prostate cancer: Is less more?

Arcangeli S
Primo
;
2016

Abstract

Moderate hypofractionation of radiotherapy is widely considered a viable alternative to conventional fractionation for the treatment of patients with organ-confined prostate cancer, but stereotactic body radiotherapy (SBRT) is rapidly emerging as a novel treatment modality for this disease. Advances in treatment planning, image guidance, target position reproducibility and on-line tracking, coupled with a compelling radiobiological rationale, have promoted SBRT as a safe and effective treatment. Dose escalation to the tumour tissue through a decreased number of radiation fractions improves patient comfort and convenience, as well as treatment cost-effectiveness, compared with conventional radiotherapy regimens. Several clinical trials have investigated moderate and extreme hypofractionation of radiotherapy in patients with prostate cancer. Evidence is accumulating which suggests that the use of moderately hypofractionated radiotherapy can be recommended regardless of cancer risk group. Regimens of extremely hypofractionated radiotherapy have shown very good short-term efficacy and safety outcomes, but appropriately designed trials with extended follow-up monitoring are required to confirm long-term outcomes.
Articolo in rivista - Articolo scientifico
Hypofractionated Radiotherapy; Prostate Cancer
English
2016
13
7
400
408
reserved
Arcangeli, S., Greco, C. (2016). Hypofractionated radiotherapy for organ-confined prostate cancer: Is less more?. NATURE REVIEWS. UROLOGY, 13(7), 400-408 [10.1038/nrurol.2016.106].
File in questo prodotto:
File Dimensione Formato  
nrurol_2016.pdf

Solo gestori archivio

Dimensione 361.59 kB
Formato Adobe PDF
361.59 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/221534
Citazioni
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 28
Social impact